Inserm
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
Systemic sclerosis (scleroderma)
FollowWhat is new in Systemic sclerosis (scleroderma) research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- 10% urea lotion plus 1% cannabidiolPhase 3 · NCT07245238
- Anifrolumab (blinded)Phase 3 · NCT05925803
- Anifrolumab (unblinded, open label)Phase 3 · NCT05925803
- BMS-986278Phase 3 · NCT06025578
- BMS-986278 PlaceboPhase 3 · NCT06025578
- Botulinum toxin A via microneedlePhase 3 · NCT07759557
- ControlPhase 3 · NCT07245238
- DivozilimabPhase 3 · NCT05726630
- BelimumabPhase 2/3 · NCT05878717
- CABA-201Phase 2/3 · NCT06328777
- clopidogrel treatmentPhase 2/3 · NCT05098704
- AdMSCPhase 2 · NCT07326033 · NCT04356755
- AlemtuzumabPhase 2 · NCT03630211
- Allogeneic NK CellsPhase 2 · NCT06991114
- AmlitelimabPhase 2 · NCT06195072
- Anti Thymocyte GlobulinPhase 2 · NCT03630211
- BI 1015550 (Nerandomilast)Phase 2 · NCT06195072
- CD19 CAR T ArmPhase 2 · NCT07493395
- CyclophosphamidePhase 2 · NCT06733935 · NCT07115745 · NCT04380831 · NCT03630211 · NCT07085104
- Extracorporeal Photopheresis (ECP)Phase 2 · NCT04986605
- GM-CSFPhase 2 · NCT03630211
- Hyperpolarized 129 Xenon GasPhase 2 · NCT07821398
- IanalumabPhase 2 · NCT06470048
- Intravenous immunoglobulinPhase 2 · NCT03630211
- MesnaPhase 2 · NCT03630211
- Oral IfetrobanPhase 2 · NCT02682511
- Oral PlaceboPhase 2 · NCT02682511
- rapcabtagene autoleucelPhase 2 · NCT06655896
- rituximabPhase 2 · NCT06655896 · NCT03630211
- SildenafilPhase 2 · NCT06954597 · NCT04797286
- ThiotepaPhase 2 · NCT03630211
- TibulizumabPhase 2 · NCT06843239
- TOP-N53Phase 2 · NCT06954597
- TOP-N53 vehiclePhase 2 · NCT06954597
- Total Body IrradiationPhase 2 · NCT03630211
- TulisokibartPhase 2 · NCT05270668
- UVADEXPhase 2 · NCT04986605
- CD19-BCMA CAR-T cells infusionPhase 1/2 · NCT06947460
- CRT-402Phase 1/2 · NCT07778446
- FludarabinePhase 1/2 · NCT06733935 · NCT07115745 · NCT07085104
- Mesenchymal stromal cellsPhase 1/2 · NCT03211793
- NKX019Phase 1/2 · NCT06733935
- PRO-203Phase 1/2 · NCT07641634
- UCMSCPhase 1/2 · NCT04356287
- umbilical cord blood CD19-BCMA CAR-T cells infusionPhase 1/2 · NCT06947473
- ALLO-329Phase 1 · NCT07085104
- Biospecimen CollectionPhase 1 · NCT03816345
- BMS-986515Phase 1 · NCT07115745
- BMS-986553Phase 1 · NCT07873931
- C-CAR168Phase 1 · NCT07854483
- CabozantinibPhase 1 · NCT03816345
- CTX112Phase 1 · NCT06925542
- FluoropyrimidinePhase 1 · NCT03816345
- HN2301 injectionPhase 1 · NCT06801119
- IpilimumabPhase 1 · NCT03816345
- LMY-922Phase 1 · NCT07729995
- NivolumabPhase 1 · NCT03816345
- Platinum CompoundPhase 1 · NCT03816345
- Platinum DoubletPhase 1 · NCT03816345
- TocilizumabPhase 1 · NCT07115745
- XmAb657Phase 1 · NCT07284797
- Allogeneic Hematopoietic Stem Cell TransplantationEarly phase 1 · NCT04380831
- Intensity-Modulated Radiation TherapyEarly phase 1 · NCT04380831
- Total-Body IrradiationEarly phase 1 · NCT04380831
- UTAA91 injectionEarly phase 1 · NCT07000682
Closest to patients
- Clinical Study of Divozilimab in Patients With Systemic SclerodermaClinical Study of Divozilimab in Patients With Systemic SclerodermaBiocad (sponsor) · 3 hospitals in RussiaPhase 3Primary completion 2024
- Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)Research Site · Mysuru, India + 142 more hospitalsPhase 3Results expected 2027
- A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary FibrosisA Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary FibrosisLocal Institution - 0521 · México, Mexico + 458 more hospitalsPhase 3Results expected 2027
Let us optimize your content
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Publication
Integrated Scaffold Redesign and iPSC-Based Screening Reveal Potent Antifibrotic Artemisinin Analogs in Systemic Sclerosis Models.
Integrated Scaffold Redesign and iPSC-Based Screening Reveal Potent Antifibrotic Artemisinin Analogs in Systemic Sclerosis Models.
ACS central science
PubMed · PMID 42799120Case report
Rapid extrusion of perforating thumb calcinosis cutis in systemic sclerosis temporally associated with hot magnesium sulfate soaks and occlusion.
Rapid extrusion of perforating thumb calcinosis cutis in systemic sclerosis temporally associated with hot magnesium sulfate soaks and occlusion.
JAAD case reports
PubMed · PMID 42857172Publication
Vitamin D Supplementation Modulates Base Excision Repair (BER) Machinery in Systemic Sclerosis: A Prospective Longitudinal Study.
Vitamin D Supplementation Modulates Base Excision Repair (BER) Machinery in Systemic Sclerosis: A Prospective Longitudinal Study.
Biochemical genetics
PubMed · PMID 42258083Publication
Quercetin attenuates skin inflammation and fibrosis in systemic sclerosis by targeting the RELA/c-Jun axis to suppress th17 cell responses.
Quercetin attenuates skin inflammation and fibrosis in systemic sclerosis by targeting the RELA/c-Jun axis to suppress th17 cell responses.
Frontiers in immunology
PubMed · PMID 42317332Publication
Association of The Vitamin D Receptor Gene BsmI and FokI Polymorphisms with Systemic Sclerosis Risk in a Tunisian Population.
Association of The Vitamin D Receptor Gene BsmI and FokI Polymorphisms with Systemic Sclerosis Risk in a Tunisian Population.
La Tunisie medicale
PubMed · PMID 42246707
Find fellow researchers
Groups with active Systemic sclerosis (scleroderma) work.
University College London
London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
University Hospital Zurich
Zurich, Switzerland
Team details appear once the team leader joins.
Is this your team? Claim it
University of Manchester
Manchester, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
University of Michigan
Ann Arbor, United States
Team details appear once the team leader joins.
Is this your team? Claim it
IRCCS Ospedale San Raffaele
Milan, Italy
Team details appear once the team leader joins.
Is this your team? Claim it
University of Zurich
Zurich, Switzerland
Team details appear once the team leader joins.
Is this your team? Claim it
University of Florence
Florence, Italy
Team details appear once the team leader joins.
Is this your team? Claim it
University of Leeds
Leeds, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
Université Paris Cité
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
Vita-Salute San Raffaele University
Milan, Italy
Team details appear once the team leader joins.
Is this your team? Claim it
The University of Texas Health Science Center at Houston
Houston, United States
Team details appear once the team leader joins.
Is this your team? Claim it